Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
Recruiting · NCT06208462 · Registry updated 2025-03-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | Neoplasms by Histologic Type, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, intrahepatic cholangiocarcinoma, neoplasm | Recruiting | Phase 2 | 2025-03-03 | NCT06208462 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Jiangsu Hengrui Pharmaceutical Co., Ltd. | 29 |
| The First Affiliated Hospital with Nanjing Medical University | 319 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Ningbo Medical Center Lihuili Hospital | Ningbo | China | 8 |
| The First Affiliated Hospital of Nanjing Medical University | Nanjing | China | 23 |
| West china hospital | Chengdu | China | 9 |